Quercetin
Ubiquitous dietary flavonoid functioning as a senolytic adjunct, anti-inflammatory, and antioxidant. Inhibits BCL-2 family anti-apoptotic proteins in senescent cells, working synergistically with dasatinib in the D+Q senolytic protocol. Also inhibits phosphodiesterases (PDEs), increasing intracellular cAMP/cGMP. Potent inhibitor of mast cell degranulation and histamine release, providing anti-allergic properties. Modulates NF-kB and NLRP3 inflammasome pathways.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- hs-crp
- wbc
- cyclosporine-use
- quinolone-antibiotics
- PMID:25754944The Achilles heel of senescent cells: from transcriptome to senolytic drugs (D+Q) — Aging Cell, 2015
- PMID:30048220Senolytics in idiopathic pulmonary fibrosis (first human senolytic trial) — EBioMedicine, 2019
- PMID:20067961Quercetin reduces illness but not immune perturbations after intensive exercise — Med Sci Sports Exerc, 2010
Quercetin has two identities. At daily doses it is a reliable anti-inflammatory flavonoid with decent human data for immune modulation and allergy management. At high intermittent doses paired with dasatinib, it becomes one half of the first senolytic protocol ever tested in humans. The Kirkland D+Q protocol used 1250mg quercetin with 100mg dasatinib for 3 consecutive days. Fisetin may be more potent as a standalone senolytic, but quercetin has the advantage of the D+Q human trial data. The bioavailability is mediocre — phytosome or bromelain-enhanced forms help.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See Quercetin in a protocol matched to you